Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.38 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.38 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.32 |
| ▸ | TUBB | P07437 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243242 | 0.77 | IKBKB (0.35) | KEAP1KMT2AMAPTMEN1CYP1A2 | |
| SCHEMBL14690901 | 0.74 | KEAP1 (0.34) | KEAP1ENPP2 | |
| SCHEMBL868397 | 0.72 | MAPT (0.35) | ENPP2MAPT | |
| SCHEMBL5154547 | 0.70 | — | — | |
| SCHEMBL133332 | 0.70 | — | — | |
| SCHEMBL5133848 | 0.69 | KEAP1 (0.52) | KEAP1CA1CA2KMT2ACA12 | |
| SCHEMBL10509635 | 0.68 | — | — | |
| SCHEMBL14645263 | 0.68 | KMT2A (0.49) | KMT2ATSHRMEN1KDM4EALDH1A1 | |
| SCHEMBL2183638 | 0.67 | — | — | |
| SCHEMBL2686757 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106636043-B | Method for producing protease | 广州立白企业集团有限公司 | 2020-04-07 | — | — | CN | claimed |
| EP-4697957-A1 | COMPOSITION COMPRISING AN ANTIMICROBIAL AGENT AND AN ALKOXYLATED AMINE | BASF SE (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-12522813-B2 | Mannanase for formulations having pH 5-12 | BASF SE (DE) | 2026-01-13 | — | — | US | disclosed |
| US-20250234861-A1 | LACTONES FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS | BASF SE (DE) | 2025-07-24 | — | — | US | disclosed |
| US-20250040539-A1 | COMPOSITION COMPRISING AN ANTIMICROBIAL AGENT AND A CARBOXAMIDE | BASF SE (DE) | 2025-02-06 | — | — | US | disclosed |
| WO-2024218124-A1 | COMPOSITION COMPRISING AN ANTIMICROBIAL AGENT AND AN ALKOXYLATED AMINE | BASF SE (DE) | 2024-10-24 | — | — | WO | disclosed |
| EP-4447676-A1 | LACTONES FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS | BASF SE (DE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4447675-A1 | COMPOSITION COMPRISING AN ANTIMICROBIAL AGENT AND A CARBOXAMIDE | BASF SE (DE) | 2024-10-23 | — | — | EP | disclosed |
| US-20240279627-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118401108-A | Lactones for enhancing the activity of antimicrobial agents | 巴斯夫欧洲公司 | 2024-07-26 | — | — | CN | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| EP-2035416-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | SCHERING CORPORATION (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008005268-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | SCHERING CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250234861-A1 | LACTONES FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS | CYP51A1, LSS, OLA1 | KEAP1 1153/4885ENPP2 2006/4885ORAI1 1156/4885 |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | KEAP1 294/4885ENPP2 3182/4885ORAI1 2380/4885 |
| US-20250040539-A1 | COMPOSITION COMPRISING AN ANTIMICROBIAL AGENT AND A CARBOXAMIDE | PDF, AADAC, NAAA | KEAP1 2696/4885ENPP2 757/4885ORAI1 2776/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | KEAP1 517/4885ENPP2 1096/4885ORAI1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.